Finding 1075652 (2023-008)

Significant Deficiency Repeat Finding
Requirement
BC
Questioned Costs
-
Year
2023
Accepted
2024-09-27

AI Summary

  • Core Issue: Lack of supervisory review and approval for 38 out of 60 expense reimbursements.
  • Impacted Requirements: Government contracts require documented approval from knowledgeable officials for all expenditures.
  • Recommended Follow-up: Implement stronger policies and controls to ensure proper segregation of duties in the review and approval process.

Finding Text

Federal Agency: U.S. Department of Health and Human Services Pass-through Agency: State of Connecticut, Department of Mental Health and Addiction Services (COVID-19) Commonwealth of Pennsylvania, Department of Drug and Alcohol Programs State of Louisiana, Department of Mental Health and Substance Abuse Services State of Oklahoma, Department of Mental Health and Substance Abuse Services Program Name (Assistance listing #): Block Grants for Prevention and Treatment of Substance Abuse (93.959) Finding 2023-008: Cash Disbursements (Significant Deficiency) Criteria: Expenses that are charged and allocated to government contracts must include evidence of review and approval by a responsible supervisory official having knowledge of the purpose of the expenditures. Statement of Condition: For 38 of our 60 samples, review and approval by a supervisory official for expense reimbursements was not performed. Cause: Procedures and internal controls associated with the review and approval of expenditures were not adequately documented. Effect: Management did not have sufficient documentation of approval for expenditures allocated to government contracts. Questioned Costs: None Perspective Information: The sampling was a statistically valid sample and represents a systemic issue. Identification of Repeat Finding: This finding is a repeat of Finding 2022-004. Recommendation: We recommend that management implement policies, controls and procedures to ensure that there is appropriate segregation of duties over the review and approval of expenditures charged to federal programs. Views of Responsible Officials: Management is in agreement with the finding. Management will enhance the policies, procedures and controls in place over the cash disbursement process to ensure appropriate segregation of duties over approvals are in place.

Categories

Internal Control / Segregation of Duties Cash Management Significant Deficiency

Other Findings in this Audit

  • 499190 2023-004
    Material Weakness Repeat
  • 499191 2023-004
    Material Weakness Repeat
  • 499192 2023-004
    Material Weakness Repeat
  • 499193 2023-004
    Material Weakness Repeat
  • 499194 2023-004
    Material Weakness Repeat
  • 499195 2023-004
    Material Weakness Repeat
  • 499196 2023-004
    Material Weakness Repeat
  • 499197 2023-005
    Material Weakness
  • 499198 2023-006
    Material Weakness Repeat
  • 499199 2023-006
    Material Weakness Repeat
  • 499200 2023-006
    Material Weakness Repeat
  • 499201 2023-006
    Material Weakness Repeat
  • 499202 2023-006
    Material Weakness Repeat
  • 499203 2023-006
    Material Weakness Repeat
  • 499204 2023-006
    Material Weakness Repeat
  • 499205 2023-007
    Material Weakness
  • 499206 2023-008
    Significant Deficiency Repeat
  • 499207 2023-008
    Significant Deficiency Repeat
  • 499208 2023-008
    Significant Deficiency Repeat
  • 499209 2023-008
    Significant Deficiency Repeat
  • 499210 2023-008
    Significant Deficiency Repeat
  • 499211 2023-008
    Significant Deficiency Repeat
  • 499212 2023-008
    Significant Deficiency Repeat
  • 499213 2023-009
    Significant Deficiency
  • 1075632 2023-004
    Material Weakness Repeat
  • 1075633 2023-004
    Material Weakness Repeat
  • 1075634 2023-004
    Material Weakness Repeat
  • 1075635 2023-004
    Material Weakness Repeat
  • 1075636 2023-004
    Material Weakness Repeat
  • 1075637 2023-004
    Material Weakness Repeat
  • 1075638 2023-004
    Material Weakness Repeat
  • 1075639 2023-005
    Material Weakness
  • 1075640 2023-006
    Material Weakness Repeat
  • 1075641 2023-006
    Material Weakness Repeat
  • 1075642 2023-006
    Material Weakness Repeat
  • 1075643 2023-006
    Material Weakness Repeat
  • 1075644 2023-006
    Material Weakness Repeat
  • 1075645 2023-006
    Material Weakness Repeat
  • 1075646 2023-006
    Material Weakness Repeat
  • 1075647 2023-007
    Material Weakness
  • 1075648 2023-008
    Significant Deficiency Repeat
  • 1075649 2023-008
    Significant Deficiency Repeat
  • 1075650 2023-008
    Significant Deficiency Repeat
  • 1075651 2023-008
    Significant Deficiency Repeat
  • 1075653 2023-008
    Significant Deficiency Repeat
  • 1075654 2023-008
    Significant Deficiency Repeat
  • 1075655 2023-009
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.243 Substance Abuse and Mental Health Services Projects of Regional and National Significance $4.58M
93.788 Opioid Str $364,943
93.959 Block Grants for Prevention and Treatment of Substance Abuse $235,860
95.010 Congressional Directives $130,281